T. Rowe Price Associates’s Ocular Therapeutix OCUL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $2.08M | Buy |
|
|||||
|
2025
Q3 | $1.54M | Buy |
|
|||||
|
2025
Q2 | $1.17M | Buy |
|
|||||
|
2025
Q1 | $922K | Sell |
|
|||||
|
2024
Q4 | $5.46M | Sell |
|
|||||
|
2024
Q3 | $8.5M | Sell |
|
|||||
|
2024
Q2 | $7.6M | Buy |
|
|||||
|
2024
Q1 | $6.03M | Buy |
|
|||||
|
2023
Q4 | $238K | Buy |
|
|||||
|
2023
Q3 | $128K | Buy |
|
|||||
|
2023
Q2 | $200K | Buy |
|
|||||
|
2023
Q1 | $202K | Sell |
|
|||||
|
2022
Q4 | $118K | Buy |
|
|||||
|
2022
Q3 | $129K | Buy |
|
|||||
|
2022
Q2 | $104K | Buy |
|
|||||
|
2022
Q1 | $98K | Buy |
|
|||||
|
2021
Q4 | $92K | Sell |
|
|||||
|
2021
Q3 | $346K | Sell |
|
|||||
|
2021
Q2 | $491K | Buy |
|
|||||
|
2021
Q1 | $540K | Buy |
|
|||||
|
2020
Q4 | $537K | Buy |
|